LPH-5 (drug)

Last updated

LPH-5
LPH-5.svg
Clinical data
Other names(S)-3-(2,5-Dimethoxy-4-(trifluoromethyl)phenyl)piperidine; (S)-2C-TFM-3PIP; (S)-β,N-Trimethylene-2C-TFM
Drug class Selective serotonin 5-HT2A receptor agonist; Serotonergic psychedelic; Hallucinogen; Antidepressant
ATC code
  • None
Legal status
Legal status
  • In general unscheduled
Identifiers
  • (S)-3-(2,5-Dimethoxy-4-(trifluoromethyl)phenyl)piperidine
CAS Number
PubChem CID
ChemSpider
ChEMBL
Chemical and physical data
Formula C14H18F3NO2
Molar mass 289.298 g·mol−1
3D model (JSmol)
  • COC1=CC([C@@]2([H])CNCCC2)=C(OC)C=C1C(F)(F)F
  • InChI=InChI=1S/C14H18F3NO2/c1-19-12-7-11(14(15,16)17)13(20-2)6-10(12)9-4-3-5-18-8-9/h6-7,9,18H,3-5,8H2,1-2H3/t9-/m1/s1
  • Key:NZKYTYHIERLZBG-SECBINFHSA-N

LPH-5, also known as (S)-3-(2,5-dimethoxy-4-(trifluoromethyl)phenyl)piperidine or as (S)-2C-TFM-3PIP, is a psychedelic drug of the phenethylamine, 2C, and 3-phenylpiperidine families which is under development for potential medical use. [1] [2] [3] [4] [5] It is a cyclized phenethylamine and is the derivative of 2C-TFM in which the β position has been connected to the amine to form a piperidine ring. [1] [2] [3]

Contents

Pharmacology

The drug acts as a potent partial agonist of the serotonin 5-HT2A receptor (Ki = 1.3 nM, EC50 Tooltip half-maximal effective concentration = 2.1–25 nM, Emax Tooltip maximal efficacy = 56–94%). [3] [6] It shows 10- to 100-fold selectivity for the 5-HT2A receptor over the serotonin 5-HT2B and 5-HT2C receptors in terms of affinity and activational potency. [3] Along with related compounds like 25CN-NBOH, DMBMPP, and TGF-8027, LPH-5 is said to be one of the few truly selective serotonin 5-HT2A receptor agonists. [1] [2] [3] [7] Owing to its high selectivity for the serotonin 5-HT2A receptor, LPH-5 is expected to avoid the cardiac and other risks of serotonin 5-HT2B receptor activation. [8] The drug robustly induces the head-twitch response as well as persistent and robust antidepressant-like effects in rodents. [3]

History

LPH-5 was patented in 2021 [6] and was first described in the scientific literature by Emil M. Ro̷rsted and colleagues in 2024. [2] These researchers are affiliated with the Danish pharmaceutical company Lophora. [2] The drug is under development by Lophora and Atai Beckley (formerly Atai Life Sciences and Beckley Psytech) for the potential treatment of major depressive disorder. [4] [5] As of May 2025, it is in phase I clinical trials for this indication. [4] [5] [9] [10] [11] In late 2025, LPH-5 was suggested as a possible alternative and replacement of DOI for use in scientific research. [12]

Analogs

LPH-5's analog LPH-48 is likewise a selective serotonin 5-HT2A receptor agonist and psychedelic with similar characteristics. [13] [14] However, this drug has a shorter duration of action than LPH-5. [14] As with LPH-5, LPH-48 is also under development by Lophora for potential medical use. [13] [14]

See also

References

  1. 1 2 3 Gumpper RH, Nichols DE (October 2024). "Chemistry/structural biology of psychedelic drugs and their receptor(s)". British Journal of Pharmacology bph.17361. doi:10.1111/bph.17361. PMID   39354889.
  2. 1 2 3 4 5 M Ro Rsted E, Jensen AA, Smits G, Frydenvang K, Kristensen JL (May 2024). "Discovery and Structure-Activity Relationships of 2,5-Dimethoxyphenylpiperidines as Selective Serotonin 5-HT2A Receptor Agonists". Journal of Medicinal Chemistry. 67 (9): 7224–7244. doi: 10.1021/acs.jmedchem.4c00082 . PMC   11089506 . PMID   38648420.
  3. 1 2 3 4 5 6 Jensen AA, Cecchi CR, Hibicke M, Bach AH, Kaadt E, Märcher-Rørsted E, et al. (June 2025). "The Selective Serotonin 5‑HT2A Receptor Agonist (S)‑3-(2,5-Dimethoxy-4-(trifluoromethyl)phenyl)piperidine (LPH-5) Induces Persistent and Robust Antidepressant-Like Effects in Rodents". ACS Pharmacology & Translational Science. 8 (6): 1791–1803. doi:10.1021/acsptsci.5c00208. PMC  12171885. PMID   40534669.
  4. 1 2 3 "LPH 5". AdisInsight. 11 November 2025. Retrieved 1 December 2025.
  5. 1 2 3 "Delving into the Latest Updates on LPH-5 with Synapse". Synapse. 15 November 2025. Retrieved 1 December 2025.
  6. 1 2 US 2021/0137908,Kristensen JL, Jensen AA, Märcher-Rørsted E,"5-HT2A Agonists for Use in Treatment of Depression.",published 13 May 2021, assigned to Lophora ApS.
  7. ↑ Fenske TG, McKee JL, Cavalco NG, Schalk SS, Bonniwell EM, Lammers JC, et al. (October 2025). "Discovery of Highly Selective 5-HT2A Agonists Using Structure-Guided Design". Journal of Medicinal Chemistry. 68 (19) acs.jmedchem.5c01855. doi:10.1021/acs.jmedchem.5c01855. PMID   40997862.
  8. ↑ Peplow M (June 2024). "Next-generation psychedelics: should new agents skip the trip?". Nature Biotechnology. 42 (6): 827–830. doi:10.1038/s41587-024-02285-1. PMID   38831049. Another problem is that some classical psychedelics are also agonists of the 5-HT2B receptor, which is expressed in heart tissue and can cause long-term cardiac problems. Kristensen's company Lophora aims to solve that with its lead compound LPH-5, a phenylethylamine derivative with an extra molecular ring that makes it less flexible. LPH-5 has a 60-fold higher selectivity for 5-HT2A over 5-HT2B.
  9. ↑ "2025 Annual Meeting American College of Clinical Pharmacology®". Clinical Pharmacology in Drug Development. 14 (S1): 1–140. September 2025. doi:10.1002/cpdd.1588. PMID   40913464.
  10. ↑ Clinical trial number NCT06722820 for "Study to Evaluate LPH-5 in Healthy Subjects" at ClinicalTrials.gov
  11. ↑ Tandrup B (28 May 2025). "Lophora Announces First Subjects Dosed in Phase 1 Clinical Trial of LPH-5 – Lophora". Lophora –. Retrieved 1 December 2025.
  12. ↑ Cameron LP, Jaster AM, Ramos R, Ullman EZ (2025). "The Utility of DOI For the Study of Serotonin 2A and 2C Receptors". Molecular Pharmacology 100093. doi:10.1016/j.molpha.2025.100093 . Retrieved 1 December 2025.
  13. 1 2 "LPH 48". AdisInsight. 22 May 2024. Retrieved 30 October 2024. LPH 48 is a ligand therapeutic which has a similar pharmacological profile as psilocybin with superior selectivity and shorter duration, being developed by [...]
  14. 1 2 3 Lophora (31 May 2024). "Lophora Submits Clinical Trial Authorisation (CTA) Application to the French Medicines Agency (ANSM) for Lead CNS Drug LPH-5" (PDF). Retrieved 30 October 2024. About LPH-48: LPH-48 is a shorter acting direct analog of LPH-5 with similar optimized characteristics and safety profile, but with a shorter duration of action. LPH-48 is designed as a fast-follower that shows significantly faster metabolism, indicating a shorter duration of action in man. LPH-48 is a representative of the same proprietary compound class as LPH-5 and is therefore endowed with the same optimized characteristics including favorable drug-like properties and a safe pharmacological profile.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.